Navigation Links
Control gene for 'conveyor belt' cells could help improve oral vaccines, treat intestinal disease
Date:6/17/2012

Scientists have found a master regulator gene needed for the development of M cells, a mysterious type of intestinal cell involved in initiating immune responses.

M cells act like "conveyor belts," ingesting bacteria and transporting substances from the gut into Peyer's patches, specialized tissues resembling lymph nodes in the intestines. Better knowledge of M cells' properties could aid research on oral vaccines and inflammatory bowel diseases.

A team of researchers at Emory University School of Medicine and RIKEN Research Center for Allergy and Immunology in Japan has identified the gene Spi-B as responsible for the differentiation of M cells.

The results are published Sunday, June 17 in the journal Nature Immunology.

"This discovery could really unlock a lot of information about the sequence of events needed for M cells to develop and what makes them distinctive," says co-author Ifor Williams, MD, PhD, associate professor of pathology and laboratory medicine at Emory University School of Medicine. "M cells have been difficult to study because they are relatively rare, they are only found within the Peyer's patches and can't be grown in isolation."

Scientists at RIKEN, led by senior author Hiroshi Ohno, MD, PhD, teamed up with Williams' laboratory, taking advantage of a discovery by Williams that a protein called RANKL, which is produced by cells in Peyer's patches, can induce M cell differentiation. Research scientist Takashi Kanaya is first author of the paper.

Kanaya and colleagues found that the gene Spi-B is turned on strongly at early stages of M cell differentiation induced by RANKL. Their suspicion of Spi-B's critical role was confirmed when they discovered that mice lacking Spi-B do not have functional M cells, and the cells in the intestines lack several other markers usually found on M cells.

"It was somewhat surprising to find Spi-B expressed in intestinal epithelial cells," Williams says. "Because Spi-B is known to be important for the development of some types of immune cells, it was thought to be expressed only in bone marrow-derived cells."

In fact, the M cells in Spi-B deficient mice can't be restored by a transplant of normal bone marrow, the researchers found. That means Spi-B has to be active in intestinal epithelial cells (not immune cells) for M cells to develop.

Williams says information about M cells in particular, what molecules they have on their surfaces could be useful for targeting oral vaccines. Most vaccines in use today are administered by injection. But immunologists believe that in some cases, it may be better to deliver vaccines through the mouth or nose, thus strengthening the body's defenses where an infection starts.

Because M cells are involved in the uptake of bacteria, the study of M cells could also guide development of treatments for inflammatory bowel diseases, in which immune responses to intestinal bacteria appear to become dysregulated.


'/>"/>
Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory University
Source:Eurekalert

Related medicine news :

1. Control of disease activity and biologic treatment increase life expectency in RA patients
2. Exercise Controls Weight in White Girls Better Than in Black Girls: Study
3. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
4. Aggressively controlling glucose levels may not reduce kidney failure in Type 2 diabetes
5. Birth Control Pills, HRT Tied to Digestive Ills
6. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
7. Novel drug candidates offer new route to controlling inflammation
8. Sooner Is Better for Controlling Obese Kids Weight: Study
9. MSU plan would control deadly tsetse fly
10. Control of gene expression: Histone occupancy in your genome
11. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: